Pharmaceutical logistics provider LogiCare3PL, a BioCare company, said on Monday that it is supporting the commercial launch of VYKAT XR, a newly FDA-approved therapy from US biopharmaceutical company Soleno Therapeutics Inc (NASDAQ:SLNO).
VYKAT XR is the first and only treatment indicated for hyperphagia in patients with Prader-Willi syndrome (PWS).
LogiCare3PL said that this milestone marks a significant advancement for the PWS community. For the first time, individuals with PWS, who live with chronic, insatiable hunger caused by hyperphagia, have access to a therapy designed to directly address this debilitating symptom.
"This is a breakthrough moment for families affected by Prader-Willi syndrome," said Kevin Kissling, LogiCare3PL vice president and general manager. "We're proud to partner with Soleno Therapeutics to help bring VYKAT XR to patients and support timely access to this long-awaited treatment."
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval